Novartis adds opthalmology buyout in year-end deal spree; Tesaro gets a speedy FDA review for niraparib
Novartis is engaged in a year-end deal run, it seems. On Tuesday morning the pharma giant followed up its Conatus pact with news that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
